Related Experiment Video
Updated: May 28, 2026
05:50
Platform Incubator with Movable XY Stage: A New Platform for Implementing In-Cell Fast Photochemical Oxidation of Proteins
Published on: May 17, 2021
Financing development stage biotechnology companies: RMs vs. IPOs
Mark J Ahn1, Robert B Couch, Wei Wu
1Atkinson Graduate School of Management, Willamette University, USA. mark@pukanapartners.com
Journal of Health Care Finance
|November 3, 2011
Summary
Reverse mergers (RMs) offer biotech firms an alternative to initial public offerings (IPOs), providing positive returns despite lower valuations and liquidity. These capital-raising methods suit high-risk, capital-intensive biotechnology companies.
Area of Science:
- Biotechnology
- Financial Markets
- Corporate Finance
Background:
- Biotechnology companies often require substantial capital for research and development.
- Accessing public capital markets is crucial for funding high-risk, capital-intensive ventures.
- Alternative financing vehicles are continuously sought to meet industry-specific financial needs.
Purpose of the Study:
- To compare reverse mergers (RMs) with initial public offerings (IPOs) as financing vehicles in the biotechnology sector.
- To analyze the financial performance, valuation, investment, and liquidity of RMs versus IPOs.
- To determine the suitability of RMs for biotechnology companies within a "pay for progress" framework.
Main Methods:
- Comparative analysis of reverse mergers and initial public offerings in the biotechnology industry.
- Examination of company size, market valuation, investment levels, abnormal returns, and liquidity measures.
- Assessment of post-merger/offering performance and lock-up period effects.
Main Results:
- Reverse mergers in biotech are smaller, with lower market valuations and less investment compared to IPOs.
- RMs demonstrate positive abnormal returns on announcement and for one year post-event.
- RMs exhibit lower liquidity, particularly during the six-month lock-up period.
Conclusions:
- Reverse mergers serve as a viable alternative financing strategy for biotechnology firms.
- RMs facilitate access to diverse investor pools for capital-intensive, high-risk biotech companies.
- The "pay for progress" environment may favor the structured access to capital provided by RMs.
Related Concept Videos
01:27Upstream Processing
Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:22Bioreactor Controls-III
Strain improvement is a foundational strategy in industrial microbiology aimed at maximizing microbial productivity, particularly because natural isolates typically yield commercially valuable products in very low concentrations. Although optimizing the culture medium and environmental conditions can improve yields, these adjustments are inherently limited by the organism’s genetic potential. As a result, the focus shifts toward genetic modifications to enhance biosynthetic capacity. The...
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
01:29Bioreactor Design and Operational System
Bioreactors are engineered vessels designed to cultivate microorganisms under controlled conditions for industrial bioprocessing. They maintain sterility and allow precise regulation of pH, temperature, oxygen, and nutrient levels to optimize microbial growth and metabolite production. Bioreactors range from small laboratory units of 1 liter to industrial systems holding up to 500,000 liters, though only about 75% of their volume is actively used for fermentation. The remaining headspace...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...